Market revenue in 2023 | USD 15.5 million |
Market revenue in 2030 | USD 19.3 million |
Growth rate | 3.2% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
Key market players worldwide | Thermo Fisher Scientific Inc, Qiagen NV, Illumina Inc, Roche Holding AG ADR, BD, Agilent Technologies Inc, Myriad Genetics Inc, Koninklijke Philips NV, Abbott Laboratories, Hitachi Ltd, Danaher Corp, Prestige Medical |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pancreatic cancer diagnostic market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 61.94% in 2023. Horizon Databook has segmented the Saudi Arabia pancreatic cancer diagnostic market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
Growth in the market can primarily be attributed to the increasing involvement of the government and the rising awareness about the benefits of noninvasive diagnostic procedures. In addition, rapid advancements in NGS and PCR technologies have improved the accuracy of diagnostic techniques over the years.
Moreover, local & international players are focusing on expanding their networks in Saudi Arabia, as awareness and adoption of advanced technologies are increasing in the country. For instance, in July 2021, Onco DNA, a leader in liquid biopsy, Bayer Saudi Arabia, & Tamkin Al-Seha Medical partnered to broaden access to biomarker testing and identify patients eligible for treatment with TRK inhibitors in Saudi Arabia.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia pancreatic cancer diagnostic market , including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia pancreatic cancer diagnostic market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account